MPT0B169 reduces Bcr-Abl expression and its downstream signaling pathways.

<p>Cells were treated with or without 2.5 μM MPT0B169 for 48 h, and the following experiments were then performed. (A) RT-PCR and (B) quantitative real-time PCR showed that MPT0B169 inhibited <i>Bcr-Abl</i> expression. Values are the mean ± SEM from three independent experiments. * <i>p</i> < 0.05 versus the untreated control. (C and D) Protein levels of Bcr-Abl and β-actin were determined by Western blotting. Western blots are representative of three experiments, and values are shown as the mean ± SEM. * <i>p</i> < 0.05 versus the untreated control. (E) Levels of phospho-Akt, Akt, phospho-ERK1/2, ERK1/2, phospho-STAT3, and STAT3 were determined. β-actin was used as a loading control. RT-PCR and Western blot analyses show one representative result of three independent experiments (A and E).